|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C25H23N5O2S
|
|||
| Molecular Weight | 457.55 | CAS No. | 848344-36-5 | |
| Solubility (25°C)* | In vitro | DMSO | 24 mg/mL (52.45 mM) | |
| Water | Insoluble | |||
| Ethanol | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | Bentamapimod (AS602801) is a novel, orally active JNK inhibitor with IC50 values of 80 nM, 90 nM and 230 nM for JNK1, JNK2 and JNK3 respectively. | ||||||
|---|---|---|---|---|---|---|---|
| Targets |
|
||||||
| In vitro | In vitro, AS602801 exhibits cytotoxicity against both serum-cultured non-stem cancer cells and cancer stem cells derived from human pancreatic cancer, non-small cell lung cancer, ovarian cancer and glioblastoma at concentrations that does not decrease the viability of normal human fibroblasts. AS602801 also inhibits the self-renewal and tumor-initiating capacity of cancer stem cells surviving AS602801 treatment[2]. |
||||||
| In vivo | Cancer stem cells in established xenograft tumors are reduced by systemic administration of AS602801 at a dose and schedule that did not adversely affect the health of the tumor-bearing mice[2]. |
Protocol (from reference)
References
|
Selleck's Bentamapimod (AS602801) has been cited by 3 publications
| JNK inhibitor IX restrains pancreatic cancer through p53 and p21 [ Front Oncol, 2022, 12:1006131] | PubMed: 36568248 |
| JNK inhibitor IX restrains pancreatic cancer through p53 and p21 [ Front Oncol, 2022, 12:1006131] | PubMed: 36568248 |
| TLR7/8-agonist-loaded Nanoparticles Promote the Polarization of Tumour-Associated Macrophages to Enhance Cancer Immunotherapy [ Nat Biomed Eng, 2018, 2(8):578-588] | PubMed: 31015631 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.